-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] A-shares have been successfully concluded in 2021.
In this year, which bull stocks have been born in the pharmaceutical industry? Let's take a look at it together! Judging from the situation of the domestic pharmaceutical sector at the end of the year, according to data from Flush, as of December 31, 2021, the China Securities Pharmaceutical Index has increased by 6.
1% during the year.
Although the increase is small, it is clearly differentiated in sub-sectors.
Outbreaks occurred, while sectors such as biomedicine, pharmaceutical commerce, and medical devices fell sharply
.
Looking back at 2021, the overall performance of the pharmaceutical sector in the A-share market is weak, and the stock prices of pharmaceutical giants such as Hengrui Medicine cannot avoid a relatively large adjustment
.
However, Jiu'an Medical has increased by more than 400% during the year
.
As of December 31, 2021, Jiu'an Medical reported 49.
55 yuan per share, with a market value of 23.
7 billion yuan, an increase of 440% during the year, and a market value of 24 billion yuan
.
It is understood that behind the soaring stock price of the stock, it is closely related to the news released by the company to test the product effect, production capacity, and forecast sales data
.
So, what kind of company is this? According to the data, Jiu'an Medical was established in August 1995 and landed on the A-share market in June 2010
.
The company is mainly engaged in the research and development, production and sales of household medical and health electronic products, as well as the production and sales of household health care equipment
.
However, financial data shows that from 2013 to 2019, the company's main business continued to lose money, with a total of -957 million yuan deducted from non-net profit in the seven years
.
In fact, in the first half of 2021, the share price of Jiu'an Medical is basically flat
.
However, in the 34 trading days from November 15th to December 30th, Jiu'an Medical has closed 23 daily limits, and only 6 trading days have been adjusted, with a cumulative increase of more than 7 times
.
On the news, on November 8, 2021, Jiu'an Medical disclosed that the kit was authorized for emergency use in the United States
.
The advantage of the product is that "anterior nasal swab samples can be collected by individuals for operation, and results can be obtained quickly in 15 minutes.
Without a prescription, they can be purchased through channels such as e-commerce, pharmacies, and supermarkets in the United States.
" related sales revenue
.
In addition, from November 11 to 15, 2021, Jiu'an Medical expressed the booming sales of home self-test kits in the United States on the interactive platform
.
According to this, some investors estimate that the monthly sales of Jiu'an Medical in the United States can reach 700 million US dollars or even 1.
4 billion US dollars, and the sales amount may reach 10 billion US dollars in a year
.
Many people in the market believe that the company's stock price may have skyrocketed due to the speculation
.
In this regard, on December 14, 2021, the Shenzhen Stock Exchange also issued a regulatory letter to Jiu'an Medical
.
The company responded on the interactive platform earlier than the time disclosed in the designated media on the progress of the kit's acquisition of the US FDA EUA authorization, and disclosed the "announcement of abnormal fluctuations in stock trading" three times, saying that there was no information that should be disclosed but not disclosed until the reply was made.
Only in the exchange's concern letter, it will be disclosed in the interactive response, and the necessary explanations and risk warnings will be given
.
However, in addition to Jiu'an Medical, there are many pharmaceutical stocks that will see gratifying gains in 2021, including Common Medicine, Sunshine Novo, Medicilon, Tofflon, Gongdong Medical, and Bairen Medical
.
Among them, the share price of Common Medicine and Sunshine Nuohe increased by 397% and 352% respectively during the year
.
In addition, Bairen Medical and Gongdong Medical in the medical device sector increased by more than 200% during the year
.
Medicilon in the CRO sector also rose by more than 200% during the year
.
In this year, which bull stocks have been born in the pharmaceutical industry? Let's take a look at it together! Judging from the situation of the domestic pharmaceutical sector at the end of the year, according to data from Flush, as of December 31, 2021, the China Securities Pharmaceutical Index has increased by 6.
1% during the year.
Although the increase is small, it is clearly differentiated in sub-sectors.
Outbreaks occurred, while sectors such as biomedicine, pharmaceutical commerce, and medical devices fell sharply
.
Looking back at 2021, the overall performance of the pharmaceutical sector in the A-share market is weak, and the stock prices of pharmaceutical giants such as Hengrui Medicine cannot avoid a relatively large adjustment
.
However, Jiu'an Medical has increased by more than 400% during the year
.
As of December 31, 2021, Jiu'an Medical reported 49.
55 yuan per share, with a market value of 23.
7 billion yuan, an increase of 440% during the year, and a market value of 24 billion yuan
.
It is understood that behind the soaring stock price of the stock, it is closely related to the news released by the company to test the product effect, production capacity, and forecast sales data
.
So, what kind of company is this? According to the data, Jiu'an Medical was established in August 1995 and landed on the A-share market in June 2010
.
The company is mainly engaged in the research and development, production and sales of household medical and health electronic products, as well as the production and sales of household health care equipment
.
However, financial data shows that from 2013 to 2019, the company's main business continued to lose money, with a total of -957 million yuan deducted from non-net profit in the seven years
.
In fact, in the first half of 2021, the share price of Jiu'an Medical is basically flat
.
However, in the 34 trading days from November 15th to December 30th, Jiu'an Medical has closed 23 daily limits, and only 6 trading days have been adjusted, with a cumulative increase of more than 7 times
.
On the news, on November 8, 2021, Jiu'an Medical disclosed that the kit was authorized for emergency use in the United States
.
The advantage of the product is that "anterior nasal swab samples can be collected by individuals for operation, and results can be obtained quickly in 15 minutes.
Without a prescription, they can be purchased through channels such as e-commerce, pharmacies, and supermarkets in the United States.
" related sales revenue
.
In addition, from November 11 to 15, 2021, Jiu'an Medical expressed the booming sales of home self-test kits in the United States on the interactive platform
.
According to this, some investors estimate that the monthly sales of Jiu'an Medical in the United States can reach 700 million US dollars or even 1.
4 billion US dollars, and the sales amount may reach 10 billion US dollars in a year
.
Many people in the market believe that the company's stock price may have skyrocketed due to the speculation
.
In this regard, on December 14, 2021, the Shenzhen Stock Exchange also issued a regulatory letter to Jiu'an Medical
.
The company responded on the interactive platform earlier than the time disclosed in the designated media on the progress of the kit's acquisition of the US FDA EUA authorization, and disclosed the "announcement of abnormal fluctuations in stock trading" three times, saying that there was no information that should be disclosed but not disclosed until the reply was made.
Only in the exchange's concern letter, it will be disclosed in the interactive response, and the necessary explanations and risk warnings will be given
.
However, in addition to Jiu'an Medical, there are many pharmaceutical stocks that will see gratifying gains in 2021, including Common Medicine, Sunshine Novo, Medicilon, Tofflon, Gongdong Medical, and Bairen Medical
.
Among them, the share price of Common Medicine and Sunshine Nuohe increased by 397% and 352% respectively during the year
.
In addition, Bairen Medical and Gongdong Medical in the medical device sector increased by more than 200% during the year
.
Medicilon in the CRO sector also rose by more than 200% during the year
.
